Rani Therapeutics Holdings Inc (RANI)

NASDAQ
18.75
-0.66(-3.40%)
After Hours
18.75
0.00(-0.01%)
- Real-time Data
  • Volume:
    247,505
  • Bid/Ask:
    15.00/20.50
  • Day's Range:
    18.75 - 20.53

RANI Overview

Prev. Close
19.41
Day's Range
18.75-20.53
Revenue
-
Open
19.22
52 wk Range
9.24-29.4
EPS
-
Volume
247,505
Market Cap
369.65M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
452,699
P/E Ratio
-
Beta
-
1-Year Change
-
Shares Outstanding
19,714,592
Next Earnings Date
Dec. 01, 2021
What is your sentiment on Rani Therapeutics Holdings Inc?
or
Market is currently closed. Voting is open during market hours.

Rani Therapeutics Holdings Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellBuyStrong Buy
Technical IndicatorsStrong SellStrong SellStrong SellSellStrong Buy
SummaryStrong SellStrong SellStrong SellNeutralStrong Buy

Rani Therapeutics Holdings Inc Company Profile

Rani Therapeutics Holdings Inc Company Profile

Employees
71

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-103, a glucagon-like peptide-1 mimetic to treat type 2 diabetes; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.